X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (160) 160
index medicus (138) 138
animals (76) 76
female (69) 69
cancer (66) 66
oncology (66) 66
chemotherapy (65) 65
immunotherapy (58) 58
immunology (56) 56
male (52) 52
bladder cancer (49) 49
plus bcg (49) 49
double-blind (46) 46
mice (41) 41
urology & nephrology (41) 41
cutaneous leishmaniasis (33) 33
phase-ii trial (33) 33
urothelial carcinoma (32) 32
vaccine (32) 32
care and treatment (31) 31
visceral leishmaniasis (31) 31
medicine, research & experimental (29) 29
transitional-cell carcinoma (29) 29
bacillus-calmette-guerin (28) 28
bcg (28) 28
infection (27) 27
middle aged (27) 27
treatment outcome (27) 27
vaccines (27) 27
controlled-trial (26) 26
gemcitabine plus cisplatin (25) 25
research (25) 25
urinary bladder neoplasms - pathology (25) 25
antigens (24) 24
antigens, protozoan - immunology (24) 24
leishmania major - immunology (24) 24
phase-iii trial (24) 24
vaccination (24) 24
leishmaniasis, cutaneous - prevention & control (23) 23
metastasis (23) 23
protozoan vaccines - immunology (23) 23
urinary bladder neoplasms - drug therapy (23) 23
adult (22) 22
antineoplastic agents - therapeutic use (22) 22
chemotherapy, adjuvant (22) 22
transitional-cell-carcinoma (22) 22
aged (21) 21
leishmaniasis (21) 21
therapy (21) 21
clinical trials as topic (20) 20
health aspects (20) 20
leishmaniasis vaccines - immunology (20) 20
mice, inbred balb c (20) 20
parasitology (20) 20
radical cystectomy (20) 20
tuberculosis (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
clinical trials (19) 19
diagnosis (19) 19
infectious diseases (19) 19
trial (19) 19
urinary bladder neoplasms - therapy (19) 19
carcinoma (18) 18
leishmaniasis, cutaneous - immunology (18) 18
major plus bcg (18) 18
medicine, general & internal (18) 18
open-label (18) 18
parasites (18) 18
parasitic diseases (18) 18
plus interferon-alpha-2b (18) 18
randomized-trial (18) 18
urology (18) 18
analysis (17) 17
drug therapy (17) 17
infections (17) 17
safety (17) 17
medicine & public health (16) 16
neoplasm staging (16) 16
protozoan vaccines - administration & dosage (16) 16
tumors (16) 16
cystectomy (15) 15
interferon-gamma (15) 15
leishmaniasis, visceral - immunology (15) 15
medicine (15) 15
adjuvants, immunologic - administration & dosage (14) 14
amazonensis vaccine (14) 14
cancer therapies (14) 14
immune-response (14) 14
microbiology (14) 14
neoadjuvant chemotherapy (14) 14
protective immunity (14) 14
surgery (14) 14
time factors (14) 14
adjuvant chemotherapy (13) 13
administration, intravesical (13) 13
bcg vaccine - therapeutic use (13) 13
combined modality therapy (13) 13
development and progression (13) 13
disease-free survival (13) 13
immunization (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 508 - 516
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 2013, Volume 31, Issue 8, pp. 1676 - 1682
Abstract Objective Intravesical bacillus Calmette-Guerin (BCG) is the gold standard for high-grade non-muscle-invasive bladder cancer (NMIBC... 
Urology | Lenalidomide | Immunotherapy | BCG | Non-muscle-invasive bladder cancer | SUPERFICIAL BLADDER-CANCER | RANDOMIZED CLINICAL-TRIALS | CHEMOTHERAPY | SITU | TRANSITIONAL-CELL-CARCINOMA | THERAPY | PLUS DEXAMETHASONE | ONCOLOGY | RADICAL CYSTECTOMY | UROLOGY & NEPHROLOGY | RELAPSED MULTIPLE-MYELOMA | PROGRESSION | Immunohistochemistry | Apoptosis - drug effects | Caspase 3 - metabolism | Microvessels - metabolism | Microvessels - pathology | BCG Vaccine - pharmacology | Thalidomide - pharmacology | Thalidomide - analogs & derivatives | Fas Ligand Protein - pharmacology | Platelet Endothelial Cell Adhesion Molecule-1 - metabolism | Urinary Bladder Neoplasms - pathology | Female | Urinary Bladder Neoplasms - metabolism | Microvessels - drug effects | Thalidomide - administration & dosage | Urinary Bladder Neoplasms - drug therapy | Blotting, Western | Mice, Inbred C3H | Drug Synergism | Tumor Necrosis Factor-alpha - pharmacology | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Tumor Necrosis Factor-alpha - administration & dosage | Cell Proliferation - drug effects | Fas Ligand Protein - administration & dosage | Mice | BCG Vaccine - administration & dosage | Angiogenesis inhibitors | Medical research | Chromatin | Cell death | Analysis | Medicine, Experimental
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2017, Volume 2017, Issue 3, p. CD012112
...‐invasive bladder cancer (NMIBC) has a high rate of recurrence and progression. Intravesical Bacillus Calmette‐Guérin (BCG... 
Bladder Cancer (Malignancy, Neoplasia): [Superficial, muscle‐invasive, metastatic | Drug Administration Schedule | Adjuvants, Immunologic | Treatment of Superficial Bladder Cancer | Neoplasm Recurrence, Local | Antineoplastic Agents | Bladder | Combined Modality Therapy | Urinary Bladder Neoplasms | Withholding Treatment | Bladder cancer | Disease Progression | Urology | Randomized Controlled Trials as Topic | Bacillus Calmette Guerin (BCG) | Time Factors | BCG Vaccine | Carcinoma in Situ | Administration, Intravesical | Medicine General & Introductory Medical Sciences | Interferon‐alpha | Cancer | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | THERAPY | PLUS INTERFERON-ALPHA-2B | URINARY-BLADDER | TRANSITIONAL-CELL CARCINOMA | UROTHELIAL CARCINOMA | BCG | RISK | RECURRENCE | EPIDEMIOLOGY | Urinary Bladder Neoplasms - mortality | Adjuvants, Immunologic - administration & dosage | Carcinoma in Situ - pathology | Humans | Withholding Treatment - statistics & numerical data | Antineoplastic Agents - administration & dosage | Carcinoma in Situ - therapy | Combined Modality Therapy - adverse effects | Adjuvants, Immunologic - adverse effects | Interferon-alpha - administration & dosage | Antineoplastic Agents - adverse effects | Urinary Bladder Neoplasms - therapy | Urinary Bladder Neoplasms - pathology | Combined Modality Therapy - methods | Interferon-alpha - adverse effects | Carcinoma in Situ - mortality
Journal Article